Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta

INTRODUCTION: Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hald, Jannie D, Keerie, Catriona, Weir, Christopher J, Javaid, Muhammad K, Lam, Wayne, Osborne, Patricia, Walsh, Jennifer, Langdahl, Bente L, Ralston, Stuart H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668140/
https://www.ncbi.nlm.nih.gov/pubmed/37993151
http://dx.doi.org/10.1136/bmjopen-2023-078164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668140/
https://www.ncbi.nlm.nih.gov/pubmed/37993151
http://dx.doi.org/10.1136/bmjopen-2023-078164

Ejemplares similares